The only way to offset this is to prioritize protein intake and incorporate strength training into your routine
The effects of GLP-1RAs on multiple human organizations, source: reference [2] Data from Novo Nordisk's Phase III clinical trial showed that liraglutide 3.0 mg resulted in a 5% weight loss in approximately 62% of obese patients and a 10% weight loss in 34% of patients after a 56-week treatment period
Its worth noting that although weight loss with tirzepatide can occur quickly, its important to maintain healthy eating routines and a good exercise plan to maximize the benefits of the treatment
PBH is also associated with a high degree of disability and can result in major disruptions to life, including falls, motor vehicle accidents, and job and income loss
304 , C508518 (2013)
As a small molecule, though, Orforglipron follows a manufacturing and regulatory pathway thats distinct from the peptide-based GLP-1 therapies highlighted in this article